fingolimod hydrochloride has been researched along with Disbacteriosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camarillo, C; Chin, B; Herrera, GV; Perez, RG; Sarosiek, I; Vidal-Martinez, G; Yang, B | 1 |
| Jia, LL; Liu, H; Pan, LL; Sun, J; Zhang, M | 1 |
2 other study(ies) available for fingolimod hydrochloride and Disbacteriosis
| Article | Year |
|---|---|
A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models.
Topics: Adult; Aged; Aged, 80 and over; Animals; Constipation; Disease Models, Animal; Dysbiosis; Female; Fingolimod Hydrochloride; Gastrointestinal Microbiome; Gastrointestinal Motility; Humans; Immunosuppressive Agents; Male; Mice; Mice, Transgenic; Microbiota; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pilot Projects; RNA, Ribosomal, 16S | 2020 |
Early-life fingolimod treatment improves intestinal homeostasis and pancreatic immune tolerance in non-obese diabetic mice.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Movement; Diabetes Mellitus, Type 1; Dysbiosis; Female; Fingolimod Hydrochloride; Gastrointestinal Microbiome; Homeostasis; Hypoglycemic Agents; Immune Tolerance; Intestines; Mice, Inbred NOD; Pancreas; Signal Transduction | 2021 |